OCUL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Ocular Therapeutix Inc (OCUL) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite recent price volatility, the stock is supported by strong analyst ratings, a promising drug pipeline nearing FDA approval, and significant hedge fund interest. The current price decline presents an attractive entry point for long-term growth.
The MACD histogram is positive and expanding (0.241), indicating bullish momentum. RSI at 69.788 is neutral, suggesting no overbought or oversold conditions. Moving averages are converging, showing no clear trend. Key resistance is at 9.447, with support at 6.751. The stock is trading near resistance levels, but the overall technical setup leans slightly bullish.
Upcoming presentation of SOL-1 Phase 3 trial results at the Macula Society Annual Meeting on February 27,
Plans to submit a New Drug Application to the FDA for AXPAXLI, which could be the first tyrosine kinase inhibitor approved for wet AMD.
Strong hedge fund buying activity, up 2312.47% last quarter.
Analysts maintain high price targets ($21-$
and positive ratings.
Insiders are selling, with a 186.05% increase in selling activity over the last month.
Revenue dropped 22.43% YoY in Q4 2025, and gross margin declined by 5.20%.
The market reaction to SOL-1 data has been negative, with concerns about Axpaxli's clinical positioning.
In Q4 2025, revenue declined by 22.43% YoY to $13.25 million. However, net income improved by 33.62% YoY to -$64.65 million, and EPS remained stable at -0.29. Gross margin dropped to 87.97%, down 5.20% YoY. The company has $737.1 million in cash and cash equivalents, providing strong financial support for R&D and market initiatives.
Analysts are bullish on OCUL, with multiple firms maintaining Buy or Outperform ratings. Price targets range from $21 to $34, significantly above the current price. Analysts view the recent selloff as an attractive entry point, emphasizing Axpaxli's potential for FDA approval and market adoption.
